secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001628280-22-021960
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab Q2 2022 revenue $48.2M (+31% YoY); net loss narrows; efgartigimod BLA accepted in China
--------------------------------------------------------------------------------

- Total revenues $48.2M (Q2 2021: $36.9M); ZEJULA revenue $34.1M (+46% YoY). Net loss $137.9M vs $163.3M.
- Cash position $1.26B; NMPA accepted BLA for efgartigimod in generalized myasthenia gravis.
- Karuna's KarXT Phase 3 EMERGENT-2 met primary endpoint: 9.6-point PANSS reduction vs placebo (p<0.0001).
- Josh Smiley appointed COO effective Aug 1; John Diekman named Lead Independent Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000162828022021960/0001628280-22-021960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000162828022021960/zlab-20220809.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-021960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer